Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7151164B2 · kind B2 · utility
201Cited by
23References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2003 |
| Grant date | Dec 19, 2006 |
| Priority date | — |
| Expiry date | Feb 5, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.